Share This Author
The development of a Clinician-Administered PTSD Scale
The Clinician-Administered PTSD Scale (CAPS-1) is a structured interview for assessing core and associated symptoms of PTSD and is intended for use by experienced clinicians, and also can be administered by appropriately trained paraprofessionals.
The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability.
In a study involving four raters and 40 patients with obsessive-compulsive disorder at various stages of treatment, interrater reliability for the total Yale-Brown Scale score and each of the 10 individual items was excellent, with high degree of internal consistency among all item scores demonstrated with Cronbach's alpha coefficient.
Antidepressant effects of ketamine in depressed patients
The Yale-Brown Obsessive Compulsive Scale. II. Validity.
Results from a previously reported placebo-controlled trial of fluvoxamine in 42 patients with obsessive-compulsive disorder showed that the Yale- Brown Scale was sensitive to drug-induced changes and that reductions in Yale-Brown Scale scores specifically reflected improvement in obsessive- compulsive disorder symptoms.
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Robust and rapid antidepressant effects resulted from a single intravenous dose of an N-methyl-D-aspartate antagonist; onset occurred within 2 hours postinfusion and continued to remain significant for 1 week.
A CLINICIAN RATING SCALE FOR ASSESSING CURRENT AND LIFETIME PTSD: THE CAPS-1
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
These data indicate that N-methyl-D-aspartate antagonists produce a broad range of symptoms, behaviors, and cognitive deficits that resemble aspects of endogenous psychoses, particularly schizophrenia and dissociative states.
Measurement of Dissociative States with the Clinician-Administered Dissociative States Scale (CADSS)
Initial analyses indicated good interrater reliability and construct validity and sensitivity of the CADSS to discriminate patients with dissociative disorders from patients with other psychiatric disorders and healthy subjects.
Psychobiological mechanisms of resilience and vulnerability: implications for successful adaptation to extreme stress.
- D. Charney
- PsychologyThe American journal of psychiatry
- 1 February 2004
An integrative model of resilience and vulnerability that encompasses the neurochemical response patterns to acute stress and the neural mechanisms mediating reward, fear conditioning and extinction, and social behavior is proposed.
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
- J. Murrough, D. Iosifescu, S. Mathew
- Psychology, MedicineThe American journal of psychiatry
- 1 October 2013
Ketamine demonstrated rapid antidepressant effects in an optimized study design, further supporting NMDA receptor modulation as a novel mechanism for accelerated improvement in severe and chronic forms of depression.